Repare Therapeutics (NASDAQ:RPTX) Given New $25.00 Price Target at Piper Sandler

Repare Therapeutics (NASDAQ:RPTX – Get Rating) had its price objective reduced by stock analysts at Piper Sandler from $40.00 to $25.00 in a report released on Tuesday, The Fly reports. Piper Sandler’s price objective points to a potential upside of 104.42% from the stock’s current price.

Several other analysts also recently issued reports on RPTX. The Goldman Sachs Group initiated coverage on Repare Therapeutics in a report on Thursday, March 17th. They issued a “buy” rating and a $43.00 price target for the company. Zacks Investment Research downgraded Repare Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Repare Therapeutics has a consensus rating of “Buy” and a consensus price target of $44.50.

RPTX stock opened at $12.23 on Tuesday. The company has a market cap of $512.14 million, a price-to-earnings ratio of -4.34 and a beta of 0.60. The business has a fifty day simple moving average of $14.06 and a 200-day simple moving average of $19.04. Repare Therapeutics has a 52 week low of $9.59 and a 52 week high of $35.75.

Repare Therapeutics (NASDAQ:RPTX – Get Rating) last announced its quarterly earnings results on Tuesday, March 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.05. Repare Therapeutics had a negative return on equity of 41.95% and a negative net margin of 1,406.68%. The firm had revenue of $6.88 million during the quarter, compared to the consensus estimate of $3.54 million. As a group, equities analysts forecast that Repare Therapeutics will post -3.58 earnings per share for the current year.

In related news, major shareholder Bvf Partners L. P/Il purchased 997,961 shares of Repare Therapeutics stock in a transaction dated Wednesday, January 19th. The shares were acquired at an average price of $14.10 per share, with a total value of $14,071,250.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 30.30% of the company’s stock.

Several hedge funds have recently modified their holdings of RPTX. Deep Track Capital LP bought a new position in shares of Repare Therapeutics during the fourth quarter worth about $44,289,000. Affinity Asset Advisors LLC bought a new position in shares of Repare Therapeutics during the fourth quarter worth about $5,732,000. Redmile Group LLC lifted its position in shares of Repare Therapeutics by 8.6% during the fourth quarter. Redmile Group LLC now owns 2,789,496 shares of the company’s stock worth $58,830,000 after purchasing an additional 221,800 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Repare Therapeutics by 237.3% during the third quarter. Franklin Resources Inc. now owns 298,609 shares of the company’s stock worth $7,836,000 after purchasing an additional 210,074 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Repare Therapeutics during the fourth quarter worth about $3,940,000. 69.41% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Read More